bioRxivImmunology
Persistent Immunogenicity of Integrase Defective Lentiviral Vectors delivering membrane tethered Native-Like HIV-1 Envelope Trimers
A. Gallinaro, M. F. Pirillo, Y. Aldon, S. Cecchetti, Z. Michelini, A. Tinari, M. Borghi, A. Canitano, P. F. McKay, R. Bona, M. F. Vescio, F. Grasso, M. Blasi, S. Baroncelli, G. Scarlatti, C. LaBranche, D. Montefiori, M. E. Klotman, R. W. Sanders, R. Shattock, D. Negri, A. Cara
Abstract
Integrase Defective Lentiviral Vectors (IDLVs) represent an attractive vaccine platform for delivering HIV-1 antigens, given their ability to induce specific and persistent immune responses in both mice and non-human primates (NHPs). Recent advances in HIV-1 immunogen design demonstrated that native-like HIV-1 Envelope (Env) trimers that mimic the structure of virion-associated Env induce neutralization breadth in rabbits and macaques. Here, we describe the development of an IDLV-based HIV-1 vaccine expressing either soluble ConSOSL.UFO.664 or membrane-tethered ConSOSL.UFO.750 native-like Env immunogens with enhanced bNAb epitopes exposure. We show that IDLV can be pseudotyped with properly folded membrane-tethered native-like UFO.750 trimers. After a single IDLV injection in BALB/c mice, IDLV-UFO.750 induced a faster humoral kinetic as well as higher levels of anti-Env IgG compared to IDLV-UFO.664. IDLV-UFO.750 vaccinated cynomolgus macaques developed unusually long-lasting anti-Env IgG antibodies, as underlined by their remarkable half-life both after priming and boost with IDLV. After boosting with recombinant ConM SOSIP.v7 protein, two animals developed neutralization activity against the autologous tier 1B ConS virus mediated by V1/V2 and V3 glycan sites responses. By combining the possibility to display stabilized trimeric Env on the vector particles with the ability to induce sustained humoral responses, IDLVs represent an appropriate strategy for delivering rationally designed antigens to progress towards an effective HIV-1 vaccine.
- organism: mouse
- organism: non-human primate
- assay: proteomics
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunogenicity, safety and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs
M. Blasi, D. Negri, … M. E. Klotman·bioRxiv·Mar 6, 2020
- Immunogenicity and Structure of a Stabilized HIV -1 clade C Env from a Pediatric Elite neutralizer in Complex with an Autologous bnAb
Swarandeep Singh, Sanjeev Kumar, … Kalpana Luthra·bioRxiv·Apr 26, 2025
- Membrane Env liposomes for immunization with HIV spikes
D. P. Leaman, A. Stano, … M. B. Zwick·bioRxiv·Nov 29, 2020
- Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics
A. Torrents de la Pena, K. Rantalainen, … A. B. Ward·bioRxiv·Dec 20, 2018
- Design and immunogenicity of an HIV-1 clade C pediatric envelope glycoprotein stabilized by multiple platforms
Sanjeev Kumar, Iván del Moral-Sánchez, … Kalpana Luthra·VaccinesPeer-reviewed·Jan 22, 2025
- Targeting HIV Env immunogens to B cell follicles in non-human primates through immune complex or protein nanoparticle formulations
J. T. Martin, C. T. Cottrell, … D. J. Irvine·bioRxiv·Feb 19, 2020